Company Information

  

Address: 2500 CROSSPARK ROAD, SUITE E126  
City: CORALVILLE 
State: IA 
Zip Code: 52241 
Telephone: 319-665-2575 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through our Ligand Activated Therapy, or LAT(TM), platform technology. We utilize our proprietary LAT platform technology to generate improved versions of U.S. Food and Drug Administration, or FDA, approved drugs in the high need areas of attention deficit hyperactivity disorder, or ADHD, pain and other central nervous system, or CNS, disorders. Our co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release, or ER, effect profiles for the treatment of ADHD. In addition, we have received FDA approval for APADAZ(TM), an immediate-release, or IR, combination product of benzhydrocodone, our prodrug of hydrocodone, and acetaminophen, or APAP. We are also advancing KP201/IR, an APAP-free IR formulation of our benzhydrocodone prodrug.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-3.81NAN/E
03/2018-3.62NAN/E
12/2017-2.96NAN/E
09/2017-2.92NAN/E
06/2017-1.33NAN/E
03/2017-2.04NAN/E
12/2016-1.13NAN/E
09/2016-3.16NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.40Total Liab/Total Assets2.10
Net Inc/Total Assets-0.83Total Liab/Inv Cap2.94
Net Inc/Inv Cap-1.16Total Liab/Comm Equity1.03
Pretax Inc/Net SalesNAInterest Coverage Ratio-4.92
Net Inc/Net SalesNACurr Debt/Equity-0.06
Cash Flow/Net SalesNALTD/Equity-1.70
SG&A/NetSalesNATotal Debt/Equity-1.76
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio4.08
Inventory TurnoverNACurrent Ratio4.08
Inventory Day SalesNANet Rec/Curr Assets0.04
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.42 3.13 2.61 3.32
Operating Income -13.91 -14.77 -8.15 -9.61
Interest Exp 1.81 1.83 1.83 1.84
Pretax Income -10.03 -26.23 -10.60 -9.99
Other Income 5.69 -9.63 -0.61 1.47
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -9.99 -26.22 -10.57 -9.98

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 29.30 35.72 43.33 46.34
Receivables - Total 0.00 1.51 2.01 2.50
Inventories - Total NA NA NA NA
Total Current Assets 30.91 39.08 47.00 50.20
Net Property, Plant & Equipment 1.84 1.92 2.00 2.09
Total Assets 34.00 42.65 52.46 59.31
Liabilities        
Accounts Payable 13.97 10.18 7.88 6.36
Debt in Current Liabilities 3.52 3.52 3.52 0.18
Total Current Liabilities 17.60 13.81 11.51 6.65
Long-Term Debt 99.20 107.75 97.67 99.34
Total Liabilities 117.55 122.33 109.97 107.41
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -200.94 -190.95 -164.73 -154.16
Treasury Stock NA NA NA NA
Total Stockholders' Equity -83.55 -79.68 -57.52 -48.10
Total Liabilities and Stockholders' Equity 34.00 42.65 52.46 59.31

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -9.15 -14.10 -6.94 -10.17
Net Cash Provided by Investing Activities 15.68 9.23 10.02 5.66
Net Cash Provided by Financing Activities 1.22 2.75 -0.04 -0.04

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-5.23--
12/20140.00-24.46--
12/20150.00-54.66-7.42
12/20160.00-16.52-1.13
12/20170.00-43.39-2.96
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18446,28039.15




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.